Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,priceHint,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,country,website,maxAge,address1,industry,address2
t0,IKNA,227644000.0,35851200,,,-9716000,,-9716000,3173000,-6547000,-9720000,-9720000,,,,,,0,3474000,13194000,10021000,4000,,-9716000,-9716000,348663000.0,66018000.0,227644000.0,22507000.0,293662000.0,36000.0,634000.0,-121055000.0,29950000.0,872000.0,281010000.0,30015000.0,9556000.0,283234000.0,2528000.0,-3426000,-839000,132528000,-1275000,132674000,118519000,-13170000,89000,-146000,1158000,-839000,253219000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.07770185,12.52 - 13.32,12.87,0.0,0.0,18,8,finmb_302325481,NasdaqGM,"Ikena Oncology, Inc.",USD,131612,96157,3.2299995,0.33541012,9.63 - 37.61,-24.75,-0.6580697,9.63,37.61,USD,2,-2.94,-4.3741493,11.251715,1.608285,0.14293687,16.142273,-3.2822733,-0.20333402,540977728,15,America/New_York,EDT,-14400000,NGM,0,False,False,12.86,1630526402,-0.010000229,13.04,13.32,12.52,144948,"Ikena Oncology, Inc.",us_market,PRE,,,,37.61,9.63,11.25,16.14,131.61k,96.16k,35.85M,,20.1M,0.09%,82.68%,1.27M,16.69,4.24%,3.54%,1.5M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-380.50%,,,9.44M,3.08,7.70%,-24.51M,-35.61M,-47.03M,,,281.01M,7.84,7.64M,3.36,9.44,,-41.12M,,Value,02210,Healthcare,38,"Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,857-273-8343,MA,United States,http://ikenaoncology.com,86400,645 Summer Street,Biotechnology,Suite 101
t-1,IKNA,-101048000.0,35851200,,,-26051000,,-26051000,2716000,-12197000,-14913000,-14913000,,,,,,0,65000,14978000,12262000,-11138000,,-26051000,-26051000,10269000.0,63473000.0,-101048000.0,21002000.0,168404000.0,22000.0,1561000.0,-111339000.0,35141000.0,872000.0,162491000.0,28332000.0,1563000.0,165969000.0,2122000.0,365000,3038000,116163000,1000000,49000,106631000,-12570000,75000,-57000,12041000,-650000,137637000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.07770185,12.52 - 13.32,12.87,0.0,0.0,18,8,finmb_302325481,NasdaqGM,"Ikena Oncology, Inc.",USD,131612,96157,3.2299995,0.33541012,9.63 - 37.61,-24.75,-0.6580697,9.63,37.61,USD,2,-2.94,-4.3741493,11.251715,1.608285,0.14293687,16.142273,-3.2822733,-0.20333402,540977728,15,America/New_York,EDT,-14400000,NGM,0,False,False,12.86,1630526402,-0.010000229,13.04,13.32,12.52,144948,"Ikena Oncology, Inc.",us_market,PRE,,,,37.61,9.63,11.25,16.14,131.61k,96.16k,35.85M,,20.1M,0.09%,82.68%,1.27M,16.69,4.24%,3.54%,1.5M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-380.50%,,,9.44M,3.08,7.70%,-24.51M,-35.61M,-47.03M,,,281.01M,7.84,7.64M,3.36,9.44,,-41.12M,,Value,02210,Healthcare,38,"Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,857-273-8343,MA,United States,http://ikenaoncology.com,86400,645 Summer Street,Biotechnology,Suite 101
t-2,IKNA,-61463000.0,35851200,,,-6945000,,-6945000,2510000,-4666000,-7176000,-7176000,,,,,,0,3227000,10403000,7893000,231000,,-6945000,-6945000,,,-61463000.0,,,,,,,,,,,,,-3072000,-117000,21000,-537000,21000,-9970000,-9874000,74000,-57000,606000,-117000,,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.07770185,12.52 - 13.32,12.87,0.0,0.0,18,8,finmb_302325481,NasdaqGM,"Ikena Oncology, Inc.",USD,131612,96157,3.2299995,0.33541012,9.63 - 37.61,-24.75,-0.6580697,9.63,37.61,USD,2,-2.94,-4.3741493,11.251715,1.608285,0.14293687,16.142273,-3.2822733,-0.20333402,540977728,15,America/New_York,EDT,-14400000,NGM,0,False,False,12.86,1630526402,-0.010000229,13.04,13.32,12.52,144948,"Ikena Oncology, Inc.",us_market,PRE,,,,37.61,9.63,11.25,16.14,131.61k,96.16k,35.85M,,20.1M,0.09%,82.68%,1.27M,16.69,4.24%,3.54%,1.5M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-380.50%,,,9.44M,3.08,7.70%,-24.51M,-35.61M,-47.03M,,,281.01M,7.84,7.64M,3.36,9.44,,-41.12M,,Value,02210,Healthcare,38,"Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,857-273-8343,MA,United States,http://ikenaoncology.com,86400,645 Summer Street,Biotechnology,Suite 101
t-3,IKNA,-61463000.0,35851200,,,-5108000,,-5108000,2283000,-3160000,-5443000,-5443000,,,,,,0,2804000,8247000,5964000,335000,,-5108000,-5108000,5601000.0,68570000.0,-61463000.0,20804000.0,85974000.0,19000.0,1266000.0,-67083000.0,44273000.0,,82083000.0,24297000.0,769000.0,85205000.0,935000.0,-3714000,-137000,21000,391000,21000,-8178000,-8041000,65000,-57000,325000,-137000,60908000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.07770185,12.52 - 13.32,12.87,0.0,0.0,18,8,finmb_302325481,NasdaqGM,"Ikena Oncology, Inc.",USD,131612,96157,3.2299995,0.33541012,9.63 - 37.61,-24.75,-0.6580697,9.63,37.61,USD,2,-2.94,-4.3741493,11.251715,1.608285,0.14293687,16.142273,-3.2822733,-0.20333402,540977728,15,America/New_York,EDT,-14400000,NGM,0,False,False,12.86,1630526402,-0.010000229,13.04,13.32,12.52,144948,"Ikena Oncology, Inc.",us_market,PRE,,,,37.61,9.63,11.25,16.14,131.61k,96.16k,35.85M,,20.1M,0.09%,82.68%,1.27M,16.69,4.24%,3.54%,1.5M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-380.50%,,,9.44M,3.08,7.70%,-24.51M,-35.61M,-47.03M,,,281.01M,7.84,7.64M,3.36,9.44,,-41.12M,,Value,02210,Healthcare,38,"Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,857-273-8343,MA,United States,http://ikenaoncology.com,86400,645 Summer Street,Biotechnology,Suite 101
